Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.6225
+0.0803 (14.81%)
Aug 15, 2025, 3:42 PM - Market open
Plus Therapeutics Revenue
Plus Therapeutics had revenue of $1.39M in the quarter ending June 30, 2025, with 8.68% growth. This brings the company's revenue in the last twelve months to $5.32M, down -3.49% year-over-year. In the year 2024, Plus Therapeutics had annual revenue of $5.82M with 18.54% growth.
Revenue (ttm)
$5.32M
Revenue Growth
-3.49%
P/S Ratio
0.96
Revenue / Employee
$247,905
Employees
21
Market Cap
37.66M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5.82M | 911.00K | 18.54% |
Dec 31, 2023 | 4.91M | 4.69M | 2,093.30% |
Dec 31, 2022 | 224.00K | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | 303.00K | -6.70M | -95.67% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PSTV News
- 8 hours ago - Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements - GlobeNewsWire
- 23 hours ago - Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights - GlobeNewsWire
- 1 day ago - Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference - GlobeNewsWire
- 15 days ago - Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic - GlobeNewsWire
- 23 days ago - Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases - GlobeNewsWire
- 5 weeks ago - Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference - GlobeNewsWire
- 5 weeks ago - Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases - GlobeNewsWire